ATE339207T1 - Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen - Google Patents

Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen

Info

Publication number
ATE339207T1
ATE339207T1 AT00983965T AT00983965T ATE339207T1 AT E339207 T1 ATE339207 T1 AT E339207T1 AT 00983965 T AT00983965 T AT 00983965T AT 00983965 T AT00983965 T AT 00983965T AT E339207 T1 ATE339207 T1 AT E339207T1
Authority
AT
Austria
Prior art keywords
neoplastic cell
taurultam
taurolidine
medication
treatment
Prior art date
Application number
AT00983965T
Other languages
German (de)
English (en)
Inventor
Paul Calabresi
James Darnowski
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE339207(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of ATE339207T1 publication Critical patent/ATE339207T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00983965T 1999-12-06 2000-12-06 Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen ATE339207T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16912899P 1999-12-06 1999-12-06
US16912299P 1999-12-06 1999-12-06
US16912799P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
ATE339207T1 true ATE339207T1 (de) 2006-10-15

Family

ID=27389609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983965T ATE339207T1 (de) 1999-12-06 2000-12-06 Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen

Country Status (9)

Country Link
US (6) US6429224B1 (OSRAM)
EP (3) EP2332542B1 (OSRAM)
JP (5) JP2003515558A (OSRAM)
AT (1) ATE339207T1 (OSRAM)
AU (2) AU784539B2 (OSRAM)
CA (3) CA2696185C (OSRAM)
DE (1) DE60030770T2 (OSRAM)
ES (2) ES2438535T3 (OSRAM)
WO (2) WO2001039762A2 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
EP1797884B1 (en) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU779362B2 (en) 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
CA2441016A1 (en) * 2001-03-15 2002-09-26 Paul Calabresi Taurine compounds
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US6753328B2 (en) * 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
EP1346745B1 (en) * 2002-03-21 2006-07-19 Ed. Geistlich Söhne Ag Für Chemische Industrie Apparatus for treatment of tumor in the central nervous system (CNS)
EP1545534B1 (en) * 2002-09-24 2007-04-18 Novartis AG Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
JP5346148B2 (ja) * 2003-03-28 2013-11-20 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 抗新生物性組成物および治療方法
US20050008684A1 (en) * 2003-07-10 2005-01-13 Claus Herdeis Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
JP2007537200A (ja) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護
WO2006009765A2 (en) * 2004-06-18 2006-01-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
CA2636217C (en) * 2006-01-06 2014-02-25 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
US20100291173A1 (en) * 2006-09-05 2010-11-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of improving renal function
CN101528195B (zh) * 2006-09-07 2012-03-28 埃德盖斯特利希索恩化学工业股份公司 羟甲基转移剂在制备治疗骨癌的药物中的用途
US20100316655A1 (en) * 2008-02-11 2010-12-16 Hall Matthew D Compounds with mdr1-inverse activity
DE102010010360A1 (de) * 2010-03-05 2011-09-08 Gamptec Gmbh Formulierungen von Taurolidin und Verfahren zu seiner Herstellung
BR112012030641B8 (pt) * 2010-06-01 2022-06-14 Geistlich Pharma Ag Usos e composições para terapia farmacêutica oral
US8852617B2 (en) 2010-09-27 2014-10-07 Geistlich Pharma Ag Antimicrobial dental care preparation
PL2861573T3 (pl) 2012-06-18 2018-02-28 Geistlich Pharma Ag Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe
PL3076969T3 (pl) * 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
KR20180105115A (ko) * 2015-10-07 2018-09-27 코르메딕스, 인코포레이티드 타우로리딘의 피부-침투성 제제
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
WO2017123635A1 (en) * 2016-01-11 2017-07-20 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
WO2018126133A1 (en) * 2016-12-29 2018-07-05 Cormedix Inc. Skin-penetrating formulation of taurolidine
CN109929804B (zh) * 2017-12-15 2020-10-16 天津医科大学肿瘤医院 一种人卵巢癌细胞系及其制备方法和应用
CN113164491A (zh) * 2018-08-28 2021-07-23 科医公司 用于治疗幼年哺乳动物体内神经母细胞瘤的方法和组合物
EP3843746A4 (en) * 2018-08-28 2022-10-19 CorMedix Inc. NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS
JP2021535167A (ja) * 2018-08-31 2021-12-16 コーメディクス・インコーポレーテッド 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release
WO2020234829A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124285A (en) 1964-10-06 1968-08-21 Geistlich Soehne Ag Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them
GB1408010A (en) 1972-11-20 1975-10-01 Geistlich Soehne Ag Sulphamoylphenyl-imidazolidinones
GB1557163A (en) 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
US4107305A (en) 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
GB1588110A (en) 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4192302A (en) * 1978-09-12 1980-03-11 Boddie Arthur W Hepatic isolation and perfusion circuit assembly
JPS5598170A (en) * 1979-01-18 1980-07-25 Mitsui Toatsu Chem Inc 5-fluorouracil derivative and its preparation
US4337251A (en) * 1979-05-09 1982-06-29 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of avoiding and removing adhesions
CA1190855A (en) 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
GB8328073D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328111D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328074D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compositions
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5573771A (en) 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
GB8827986D0 (en) 1988-11-30 1989-01-05 Geistlich Soehne Ag Chemical product
US5819748A (en) 1988-11-30 1998-10-13 Ed Geistlich Sohne Ag Fur Chemische Industrie Implant for use in bone surgery
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
DE69104608T2 (de) * 1991-07-04 1995-02-16 Weissenfluh Hawe Neos Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis.
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
GB9216155D0 (en) * 1992-07-30 1992-09-09 Geistlich Soehne Ag Treatment of dentoalveolar infections
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5954687A (en) 1995-04-28 1999-09-21 Medtronic, Inc. Burr hole ring with catheter for use as an injection port
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
GB9600426D0 (en) 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
DE19606897C2 (de) * 1996-02-13 2002-08-29 Geistlich Soehne Ag Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren
US6303596B1 (en) * 1997-05-22 2001-10-16 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6011030A (en) 1997-09-22 2000-01-04 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating symptoms of microbial infection or sepsis
US5972933A (en) 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6117868A (en) 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose

Also Published As

Publication number Publication date
US6964959B2 (en) 2005-11-15
CA2696185A1 (en) 2001-06-07
AU784538B2 (en) 2006-04-27
JP6234340B2 (ja) 2017-11-22
WO2001039762A2 (en) 2001-06-07
ES2531547T3 (es) 2015-03-17
AU2065001A (en) 2001-06-12
EP2332542B1 (en) 2015-02-11
JP2003515558A (ja) 2003-05-07
JP2012136540A (ja) 2012-07-19
ES2438535T3 (es) 2014-01-17
US6995164B2 (en) 2006-02-07
JP5027369B2 (ja) 2012-09-19
US6429224B1 (en) 2002-08-06
DE60030770T2 (de) 2007-09-06
EP2332542A2 (en) 2011-06-15
WO2001039763A3 (en) 2002-07-11
US6703413B2 (en) 2004-03-09
JP2014198739A (ja) 2014-10-23
EP2332542A3 (en) 2011-09-28
EP1246617A2 (en) 2002-10-09
CA2393252A1 (en) 2001-06-07
EP1246617B1 (en) 2006-09-13
JP2003515557A (ja) 2003-05-07
US20020052366A1 (en) 2002-05-02
US20030100551A1 (en) 2003-05-29
AU784539B2 (en) 2006-04-27
US20020111345A1 (en) 2002-08-15
WO2001039762A3 (en) 2002-05-02
JP5829948B2 (ja) 2015-12-09
CA2393159A1 (en) 2001-06-07
WO2001039763A2 (en) 2001-06-07
CA2393159C (en) 2010-04-20
US20060135513A1 (en) 2006-06-22
CA2696185C (en) 2014-09-23
DE60030770D1 (de) 2006-10-26
US6521616B2 (en) 2003-02-18
JP2016188244A (ja) 2016-11-04
US20030078257A1 (en) 2003-04-24
AU2064901A (en) 2001-06-12
US20020049200A1 (en) 2002-04-25
EP1248625A2 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
ATE339207T1 (de) Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
ATE94387T1 (de) Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
ATE241353T1 (de) Fumarsäurederivate zur behandlung der transplantatabstossung
ATE316786T1 (de) Behandlung von mukositis
AR035863A1 (es) Ligandos receptores de melanocortina
DE602004012816D1 (de) Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
CY1109413T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
DE69728782D1 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
DE60119896D1 (de) Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
Wang et al. Preparation of decellularized vascular matrix by co-crosslinking of procyanidins and glutaraldehyde
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
WO2001035995A3 (en) Tr3-specific binding agents and methods for their use
AR026337A1 (es) Benzoil-ciclohexanodionas y benzoil-pirazoles, procedimiento para su preparacion y su utilizacion como herbicidas y reguladores del crecimiento de lasplantas
DE69307674D1 (de) HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS
WO2005055877A3 (de) Verfahren zur herstellung von bandscheibengewebe aus degeneriertem bandscheibengewebe
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60206245D1 (de) Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen
DE60213766D1 (de) Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
DE60217904D1 (de) Verwendung von quinazolinen zur behandlung von t-zell vermittelten krankheiten
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1246617

Country of ref document: EP